Biomedical Non-Dilutive Funding

Complete a focused intervention that advances Biomedical Non-Dilutive Funding. The objective is to remove ambiguity around scientific rationale, public health impact, regulatory pathway and milestones, give the founder a decision-ready output, and make it clear whether the venture should progress, repeat the task with stronger evidence, escalate to expert support, or move into a linked stage.

Bertie or a programme manager assigns Biomedical Non-Dilutive Funding when the venture needs a decision-ready output for this group. Typical triggers include group-gate reviews, evidence gaps identified by the co-pilot or founder request.

venture thesis; customer evidence; product roadmap; financial assumptions; current funding objective; specific context for scientific rationale, public health impact, regulatory pathway and milestones.

1. 1Clarify the Scope and Strategy for Non-Dilutive Fundingexpand_more

   Establish the exact strategic objectives for securing biomedical grant funding and non-dilutive capital for the venture. Define how non-dilutive funds will de-risk core scientific and clinical milestones without compromising equity or operational autonomy. Map out the specific grant bodies, such as Innovate UK or the NIHR, that align with the venture's technology readiness level.

   Objective

   Defining the precise scope prevents wasted effort on misaligned grant calls and misdirected proposals. This foundational clarity ensures the non-dilutive funding strategy directly reinforces the overarching venture valuation and investor readiness timeline.

   What's expected

   Produce a strategic brief detailing the non-dilutive target landscape, target grant funds, and explicit operational objectives for the capital. The output must clearly articulate how securing these funds protects founder equity while advancing technology validation.

   Consultant stress-test · 5 questions

   1. 1.What specific scientific or clinical milestone will this non-dilutive funding de-risk before you raise your next equity round?
   2. 2.How did you determine that non-dilutive grant funding is more appropriate for this development stage than dilutive venture capital?
   3. 3.Which specific funding bodies or grant programmes have you shortlisted, and why do their scope requirements match your current technology readiness level?
   4. 4.How does securing this non-dilutive capital preserve your equity cap table and improve your post-money valuation in subsequent investment rounds?
   5. 5.What operational risks or delays might arise if grant body approval takes longer than your current cash runway allows?

   Open action arrow_forward
2. 2Align Scientific, Regulatory and Public Health Strategyexpand_more
3. 3Assemble Essential Scientific, Regulatory and Financial Inputsexpand_more
4. 4Synthesise the Biomedical Non-Dilutive Funding Strategyexpand_more
5. 5Stress-Test Proposal Quality and Evidence Strengthexpand_more
6. 6Deposit Funding Assets and Determine Next Taskexpand_more

• A data-room asset titled Biomedical Non-Dilutive Funding
• A clear task output, updated venture DNA and recommended next action
• It should update the venture DNA with specific evidence or decisions about scientific rationale, public health impact, regulatory pathway and milestones, create a visible milestone in the founder journey, and generate one or more recommended next tasks

A mentor or evaluator can review the output at the group gate. Programme managers can require an advisor checkpoint before Bertie moves the venture forward.

Draft your output and let Bertie review it